相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the Treg-dendritic cell axis
Michael W. Knitz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models
Sarah Greene et al.
CLINICAL CANCER RESEARCH (2020)
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
Anthony R. Cillo et al.
IMMUNITY (2020)
CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target
Wen Zhang et al.
CANCER COMMUNICATIONS (2020)
Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8(+) T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy
Marianne Weulersse et al.
IMMUNITY (2020)
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou et al.
MOLECULAR CANCER (2020)
STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer
Ayman J. Oweida et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
STAT3 inhibition enhances CDN-induced STING signaling and antitumor immunity
Jianwen Pei et al.
CANCER LETTERS (2019)
Characterization of immune cell subtypes in three commonly used mouse strains reveals gender and strain-specific variations
Jonathan A. Hensel et al.
LABORATORY INVESTIGATION (2019)
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Katie L. Owen et al.
CANCERS (2019)
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
Anna E. Vilgelm et al.
FRONTIERS IN IMMUNOLOGY (2019)
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy
Ryuma Tokunaga et al.
CANCER TREATMENT REVIEWS (2018)
NKp46 Receptor-Mediated Interferon-gamma Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis
Ariella Glasner et al.
IMMUNITY (2018)
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies
Jay Friedman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
Ayman Oweida et al.
CLINICAL CANCER RESEARCH (2018)
Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model
Kun-Yu Teng et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Expression and function of NKp46 W32R: the human homologous protein of mouse NKp46 W32R (Noe)
Ariella Glasner et al.
Scientific Reports (2017)
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Abigail E. Overacre-Delgoffe et al.
CELL (2017)
CD69: from activation marker to metabolic gatekeeper
Danay Cibrian et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2017)
Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab
David I. Rosenthal et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations
Jessica L. Geiger et al.
ORAL ONCOLOGY (2016)
The head and neck cancer immune landscape and its immunotherapeutic implications
Rajarsi Mandal et al.
JCI INSIGHT (2016)
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
S. J. Thomas et al.
BRITISH JOURNAL OF CANCER (2015)
Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation
Shiguo Zhu et al.
BLOOD (2014)
Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance
Dagmar Gotthardt et al.
BLOOD (2014)
Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522
K. Kian Ang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
PROGNOSTIC SIGNIFICANCE OF NUCLEAR pSTAT3 IN ORAL CANCER
Muzafar A. Macha et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Maturation of mouse NK cells is a 4-stage developmental program
Laura Chiossone et al.
BLOOD (2009)
The function of Stat3 in tumor cells and their microenvironment
Bernd Groner et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma
L. Tang et al.
GENE THERAPY (2007)
Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells
Yan Zeng et al.
CANCER RESEARCH (2007)
Stat3 as a potential target for cancer immunotherapy
Marcin Kortylewski et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma
Tomoya Tsuchiyama et al.
JOURNAL OF IMMUNOLOGY (2007)
Functional subsets of mouse natural killer cells
Yoshihiro Hayakawa et al.
IMMUNOLOGICAL REVIEWS (2006)
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn et al.
BLOOD (2006)
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
M Kortylewski et al.
NATURE MEDICINE (2005)
Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects
L Burdelya et al.
JOURNAL OF IMMUNOLOGY (2005)
Innate immune response in Th1- and Th2-dominant mouse strains
H Watanabe et al.
SHOCK (2004)
KEGG: Kyoto Encyclopedia of Genes and Genomes
M Kanehisa et al.
NUCLEIC ACIDS RESEARCH (2000)
分享论文
